The Vancouver digital health company has real scale and real growth. Whether the stock re-rates depends on whether profit catches up to revenue.

WELL Health Technologies (TSX: WELL) is one of the larger and more established names on this list, with a market capitalization in the $1.0 to $1.1 billion range and a business built around owning and operating primary healthcare clinics across Canada and the U.S., alongside EMR (electronic medical record) software sold to independent clinics and doctors.

Real operational momentum

The company's recent updates point to genuine progress: WELL's Canadian operations reportedly hit a $100 million annualized adjusted EBITDA run-rate ahead of schedule, and the company has reported record Canadian patient visits alongside primary care margin expansion in its most recent quarters. Its Wellstar billing-platform subsidiary has been expanding, recently growing to serve six provinces through further acquisitions, and the board approved a normal course issuer bid — a share buyback program, which signals management believes the stock is undervalued at current levels relative to its own cash position.

The valuation tension

WELL's trailing price-to-earnings ratio has sat around 40, which is a rich multiple for a healthcare services business, but its forward P/E drops to roughly 12 — a sizable gap that reflects the market pricing in meaningful earnings growth ahead. Whether that growth materializes as projected is really the central question for the stock. Analyst sentiment has been genuinely split: of recent published opinions, roughly half have recommended buying and the rest have leaned toward selling, which is a wider divergence than most established, billion-dollar-plus companies see.

What to watch

The stock has been volatile within a 52-week range roughly between $3.58 and $6.08, more than a 50% swing from trough to peak, so entry timing matters more here than for a steadier large-cap. The concrete things worth tracking are whether the $100 million EBITDA run-rate holds and grows, Wellstar's continued provincial expansion, and whether forward earnings estimates actually get met rather than revised down — a pattern of earnings beats would likely close the gap between the stock's rich trailing multiple and its much cheaper forward one.